Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Mar;10(3):161-166.
doi: 10.1097/GIM.0b013e318163487d.

Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers

Angela R Bradbury #  1   2 , Comfort N Ibe #  1   2 , James J Dignam  3 , Shelly A Cummings  1   2 , Marion Verp  1   4 , Melody A White  1   2 , Grazia Artioli  5 , Laura Dudlicek  1   2 , Olufunmilayo I Olopade  1   2
Affiliations

Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers

Angela R Bradbury et al. Genet Med. 2008 Mar.

Abstract

Purpose: To evaluate prophylactic salpingo-oophorectomy uptake and timing among BRCA1/2 mutation carriers in a cancer risk assessment program.

Methods: Clinical records of female BRCA1/2 mutation carriers who received cancer genetic counseling between 1996 and 2003 were reviewed to determine the completion and the timing of prophylactic salpingo-oophorectomy. Logistic regression models evaluated associations between subject characteristics and surgery. Survival analysis methods were used to estimate the distribution of time to surgery.

Results: Among 88 women, 70% underwent prophylactic salpingo-oophorectomy. Prophylactic salpingo-oophorectomy was associated with older age, white race, having children, and a family history of ovarian cancer. Many women waited more than 12 months to undergo surgery and some delayed by several years. Younger age and not having children were associated with delays to surgery.

Conclusion: Prophylactic salpingo-ooporectomy is an acceptable risk reduction measure for many BRCA1/2 mutation carriers. Some women make this decision many years after genetic testing. Continued discussion of the risks and benefits of risk reduction options may facilitate the uptake of recommended risk reduction interventions among BRCA mutation carriers.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Time to bilateral salpingo-oophorectomy.
Fig. 2
Fig. 2
Time to bilateral salpingo-oophorectomy (A) by age at testing and (B) by child bearing history.
See this image and copyright information in PMC

References

    1. Whittemore AS. Risk of breast cancer in carriers of BRCA gene mutations. N Engl J Med. 1997;337:788–789. - PubMed
    1. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;56:265–271. - PMC - PubMed
    1. Ford D, Easton DF, Stratton M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676–689. - PMC - PubMed
    1. Antoniou A, Pharoah PD, Narod S. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130. - PMC - PubMed
    1. American Cancer Society . Cancer facts and figures 2007. American Cancer Society; Oakland, CA: 2006.

Publication types